On October 9, 2023 Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, reported that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA (Press release, Kineta, OCT 9, 2023, View Source;utm_medium=rss&utm_campaign=kineta-to-present-preclinical-data-on-vista-blocking-kva12123-at-immuno-us-2023 [SID1234635721]). Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present a preclinical overview of KVA12123, the company’s novel VISTA blocking immunotherapy, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Presentation Title: Anti-VISTA Monoclonal Antibody Program
Session: Discovery & Development: Cell Therapies & Antibody Approaches
Session location: Conference Room 3
Presenter: Thierry Guillaudeux, Ph.D.
Date / Time: Thursday, October 12 at 9:50-10:15 A.M. Pacific Time